{"ticker": {"uuid": "9ea60f2e-1441-41d0-831e-26c2cc6d0c61", "symbol": "ELDN", "name": "Eledon Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Microcap Value Benchmark Index", "summary": "Eledon Pharmaceuticals, Inc. (NasdaqCM:ELDN) has been removed from the Russell Microcap Value Benchmark Index, as well as the Russell Small Cap Comp Value Benchmark and Russell 3000 Value Benchmark Indices. This news follows several recent developments for the company, including ", "url": "https://www.marketscreener.com/news/eledon-pharmaceuticals-inc-nasdaqcm-eldn-dropped-from-russell-microcap-value-benchmark-index-ce7f5fdfd989f72d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:10:11", "published_display": "29 Jun 2026 13:10", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Small Cap Comp Value Benchmark", "summary": "Eledon Pharmaceuticals, Inc. (NasdaqCM:ELDN) has been removed from the Russell Small Cap Comp Value Benchmark. The company, a clinical-stage biopharmaceutical firm, focuses on immune-modulating therapies, with its lead product, tegoprubart, targeting CD40 Ligand. This news follow", "url": "https://www.marketscreener.com/news/eledon-pharmaceuticals-inc-nasdaqcm-eldn-dropped-from-russell-small-cap-comp-value-benchmark-ce7f5fdede8af226", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:13:31", "published_display": "29 Jun 2026 10:13", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 2000 Value Benchmark", "summary": "Eledon Pharmaceuticals, Inc. (NasdaqCM:ELDN) has been removed from the Russell 2000 Value Benchmark Index. This news follows several other announcements detailing the company's removal from various Russell indices, including the Microcap Value, Small Cap Comp Value, 3000 Value, 3", "url": "https://www.marketscreener.com/news/eledon-pharmaceuticals-inc-nasdaqcm-eldn-dropped-from-russell-2000-value-benchmark-ce7f5fdcd889f320", "source_name": "marketscreener.com", "published_at": "2026-06-29T00:11:54", "published_display": "29 Jun 2026 00:11", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Are Bullish on Top Healthcare Picks", "summary": "Wall Street analysts are showing bullish sentiment towards two healthcare companies, Definium Therapeutics (DFTX) and Eledon Pharmaceuticals (ELDN). LifeSci Capital maintained a Buy rating on Definium Therapeutics with a $63.00 price target, while also reaffirming a Buy rating on", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3023453/wall-street-analysts-are-bullish-on-top-healthcare-picks/", "source_name": "The Globe and Mail", "published_at": "2026-06-28T14:39:26", "published_display": "28 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Eledon Pharmaceuticals, Inc. \u2013 NASDAQ:ELDN", "summary": "This article provides financial information for Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), specifically focusing on its Price to Sales (forward) metric. It appears to be a data point from TradingView, offering a snapshot of the company's valuation from a financial perspective. ", "url": "https://www.tradingview.com/symbols/NASDAQ-ELDN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T01:09:15", "published_display": "28 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $8", "summary": "LifeSci Capital has reiterated its Buy rating on Eledon Pharmaceuticals (ELDN.US), maintaining a target price of $8. This indicates the firm's continued confidence in the company's stock performance.", "url": "https://www.moomoo.com/news/post/72135951/lifesci-capital-maintains-eledon-pharmaceuticals-eldnus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-27T23:10:12", "published_display": "27 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Eledon Pharmaceuticals, Inc. \u2013 NASDAQ:ELDN", "summary": "The article discusses the enterprise value to EBITDA forward for Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN). It appears to be a truncated financial data page from TradingView, providing an overview of the company's financial metric without detailed analysis or figures. The conte", "url": "https://www.tradingview.com/symbols/NASDAQ-ELDN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T22:10:57", "published_display": "27 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Eledon Pharmaceuticals, Inc. \u2013 NASDAQ:ELDN", "summary": "This page displays financial information for Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), specifically its Enterprise Value to EBIT forward. It indicates that the market was closed with no trades at the time of viewing. The content also features various navigation and information", "url": "https://www.tradingview.com/symbols/NASDAQ-ELDN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T12:40:22", "published_display": "27 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Eledon Pharmaceuticals, Inc. \u2013 SWB:2TK", "summary": "This article provides an analysis of the Enterprise Value to Revenue (EV/R) forward for Eledon Pharmaceuticals, Inc. (SWB:2TK). It presents the current value and changes in this financial metric for the company, indicating insights for potential investors or analysts.", "url": "https://www.tradingview.com/symbols/SWB-2TK/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:40:31", "published_display": "27 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Natera (NTRA) Partners With Eledon To Put Prospera Into Phase 3 Kidney Trial", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Eledon Pharmaceuticals, Inc. \u2013 NASDAQ:ELDN", "summary": "This article displays the \"Price to earnings forward\" value for Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) on TradingView. It provides a quick overview of this financial metric for the company. The page appears to be a financial data snippet from a larger platform rather than a ", "url": "https://www.tradingview.com/symbols/NASDAQ-ELDN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T02:39:26", "published_display": "27 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Eledon Pharmaceuticals, Inc. \u2013 SWB:2TK", "summary": "This article focuses on the enterprise value to EBIT forward for Eledon Pharmaceuticals, Inc. (SWB:2TK) on the Stuttgart Stock Exchange. It provides a financial overview and market data, indicating that the market is currently closed with no trades. The content highlights the sto", "url": "https://www.tradingview.com/symbols/SWB-2TK/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T14:10:06", "published_display": "26 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Natera\u2019s Prospera test selected for Eledon kidney transplant trial", "summary": "Natera's Prospera kidney transplant assessment test has been chosen for Eledon Pharmaceuticals' upcoming Phase 3 clinical trial of tegoprubart. This trial, set to begin in late 2026 and enrolling 600 kidney transplant recipients globally, will use Prospera as the sole donor-deriv", "url": "https://www.investing.com/news/company-news/nateras-prospera-test-selected-for-eledon-kidney-transplant-trial-93CH-4760264", "source_name": "Investing.com", "published_at": "2026-06-25T14:41:56", "published_display": "25 Jun 2026 14:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ELDN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Eledon Pharmaceuticals, Inc. (ELDN) stock, including analyst price targets, historical performance, and financial data. It highlights the current stock price, recent changes, market capitalization, and upcoming earnings report. The analysis al", "url": "https://www.tradingview.com/symbols/NASDAQ-ELDN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:41:56", "published_display": "25 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Natera, Eledon Partner to Use Prospera in Phase 3 Kidney Transplant Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/natera-eledon-partner-prospera-phase-120547526.html", "source_name": "MT Newswires", "published_at": "2026-06-25T12:05:47+00:00", "published_display": "25 Jun 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Natera and Eledon Announce Strategic Partnership for Prospera\u2122 Monitoring in Planned Phase 3 Kidney Transplant Trial", "summary": "Natera and Eledon Pharmaceuticals have announced a strategic partnership to integrate Natera's Prospera kidney transplant assessment test into Eledon's upcoming Phase 3 clinical trial for tegoprubart, an investigational therapy aimed at preventing organ rejection. Prospera will s", "url": "https://www.businesswire.com/news/home/20260625033359/en/Natera-and-Eledon-Announce-Strategic-Partnership-for-Prospera-Monitoring-in-Planned-Phase-3-Kidney-Transplant-Trial", "source_name": "Business Wire", "published_at": "2026-06-25T10:41:56", "published_display": "25 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon trial will use Natera\u2019s Prospera test to track kidney rejection", "summary": "Natera and Eledon Pharmaceuticals have announced a strategic partnership for Eledon's planned Phase 3 kidney transplant trial. Natera's Prospera test, which detects early signs of rejection and allograft injury, will be the exclusive donor-derived cell-free DNA (dd-cfDNA) monitor", "url": "https://www.stocktitan.net/news/ELDN/natera-and-eledon-announce-strategic-partnership-for-prospera-tm-eczhnhkzl2ds.html", "source_name": "Stock Titan", "published_at": "2026-06-25T10:41:56", "published_display": "25 Jun 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10", "summary": "Noble Financial has reiterated its Buy rating for Eledon Pharmaceuticals (ELDN.US) and maintained its price target at $10. This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/71902043/noble-financial-maintains-eledon-pharmaceuticals-eldnus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-24T08:41:19", "published_display": "24 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation - Slideshow (NASDAQ:ELDN) 2026-06-22", "summary": "Eledon Pharmaceuticals, Inc. (ELDN) has released updated long-term data from its Phase 2 BESTOW clinical trial in kidney transplantation, which was presented in a slideshow. The trial's findings are significant for the company and its investors, highlighting ongoing developments ", "url": "https://seekingalpha.com/article/4916843-eledon-pharmaceuticals-inc-eldn-discusses-updated-long-term-data-from-phase-2-bestow-clinical", "source_name": "Seeking Alpha", "published_at": "2026-06-23T02:41:19", "published_display": "23 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon (NASDAQ: ELDN) holders approve share increase and board slate", "summary": "Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) stockholders approved increasing authorized common stock from 300 million to 450 million shares and re-elected three Class III directors (David-Alexandre C. Gros, M.D., Jan Hillson, M.D., and James Robinson) at their annual meeting on J", "url": "https://www.stocktitan.net/sec-filings/ELDN/8-k-eledon-pharmaceuticals-inc-reports-material-event-861091862cb6.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:41:19", "published_display": "22 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon reports Phase 2 BESTOW kidney transplant data", "summary": "Eledon Pharmaceuticals announced positive long-term Phase 2 extension data for tegoprubart in kidney transplant patients, showing higher kidney function compared to traditional tacrolimus regimens. The company's shares rose following the announcement, and they plan to use these r", "url": "https://grafa.com/en/news/united-states/eledon-pharmaceuticals-phase-2-bestow-kidney-transplant", "source_name": "grafa.com", "published_at": "2026-06-22T16:40:11", "published_display": "22 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals Announces Long-Term Extension Phase 2 BESTOW Results for Tegoprubart in Kidney Transplantation", "summary": "Eledon Pharmaceuticals announced positive long-term data from its Phase 2 BESTOW clinical program for tegoprubart in kidney transplant patients. Results showed tegoprubart-treated patients maintained significantly higher mean eGFR and had fewer adverse events and no biopsy-proven", "url": "https://www.marketscreener.com/news/eledon-pharmaceuticals-announces-long-term-extension-phase-2-bestow-results-for-tegoprubart-in-kidne-ce7f5cd3df8cf62d", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T13:40:11", "published_display": "22 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Eledon Pharmaceuticals stock rating on kidney transplant data", "summary": "Cantor Fitzgerald has reiterated an Overweight rating on Eledon Pharmaceuticals (NASDAQ:ELDN) following positive Phase 2 study data for its kidney transplant drug candidate, tegoprubart. The drug showed stable to improved kidney function compared to standard-of-care tacrolimus. E", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-eledon-pharmaceuticals-stock-rating-on-kidney-transplant-data-93CH-4752620", "source_name": "Investing.com", "published_at": "2026-06-22T12:40:11", "published_display": "22 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus", "summary": "Eledon Pharmaceuticals announced that mid-stage data for its drug tegoprubart in kidney transplantation showed higher kidney function and improved outcomes compared to tacrolimus. The company's lead investigational product, tegoprubart, is an IgG1, anti-CD40L antibody aimed at im", "url": "https://www.marketscreener.com/news/eledon-says-mid-stage-data-shows-tegoprubart-offers-higher-kidney-function-improved-outcomes-compar-ce7f5cd3dc8ffe2d", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T12:40:11", "published_display": "22 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/eledon-presents-long-term-extension-110000322.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T11:00:00+00:00", "published_display": "22 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon reports kidney function benefit for tegoprubart at 18 months", "summary": "Eledon Pharmaceuticals Inc. presented positive long-term data from its Phase 2 BESTOW clinical trial, showing that tegoprubart-treated kidney transplant patients had significantly better kidney function at 18 months compared to those treated with tacrolimus. The company's shares ", "url": "https://www.investing.com/news/company-news/eledon-reports-kidney-function-benefit-for-tegoprubart-at-18-months-93CH-4752243", "source_name": "Investing.com", "published_at": "2026-06-22T11:40:11", "published_display": "22 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Presents Long-Term Extension Phase 2 BESTOW Results", "summary": "Eledon Pharmaceuticals announced new long-term data from its Phase 2 BESTOW clinical program for tegoprubart in kidney transplant patients, presented at the American Transplant Congress. The data showed sustained higher kidney function, no biopsy-proven acute rejection events aft", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315172/0/en/eledon-presents-long-term-extension-phase-2-bestow-results-at-american-transplant-congress-showing-sustained-higher-kidney-function-and-improved-patient-reported-outcomes-with-tego.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T10:40:11", "published_display": "22 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink raises Eledon Pharmaceuticals price target on trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOSnJrUVFMTjN0ZjZnYUhPc05EZHdsa2dMdEJ6b1VlZy1TOXlESndDQjJhRDF4OGhyOHNaZ2lVMDVRWkQyLUc2OWlJVXpGVUI1OG14TzY1SDdHYzRuMERzYVBUcWhXbER6anp0WGhlZERVT0E0SjZSUGVyNnBmdXF4VlVicm9oZXBBMFRtMmU2UWxVLVR5Y3FQNWg4TEk4ZGl0REdOUE5Ub1dLZXJhZjF6LUF4ZDRQNmQtZWpZNlVVTWRrUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharma To Present At The American Transplant Congress", "summary": "Eledon Pharmaceuticals Inc. (ELDN) is scheduled to present at the American Transplant Congress (ATC) from June 20-24, 2026, in Boston. The company will host a conference call on June 22, 2026, to discuss updated data from the Phase 2 BESTOW clinical trial and new long-term data f", "url": "https://www.rttnews.com/3661226/eledon-pharma-to-present-at-the-american-transplant-congress.aspx", "source_name": "RTTNews", "published_at": "2026-06-18T12:09:01", "published_display": "18 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals Inc (ELDN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Eledon Pharmaceuticals Inc (ELDN)'s dividend and stock split history. It states that no dividends have been distributed in the past five years and details several \"Merger 18\u21921\" stock splits that occurred on October 2, 2020. The company's curre", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eldn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:02", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals Inc (ELDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses Eledon Pharmaceuticals Inc (ELDN)'s revenue breakdown, noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It provides current stock performance figures for ELDN, includ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eldn/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:55", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals Inc (ELDN) Institutional Confidence", "summary": "Eledon Pharmaceuticals Inc (ELDN) has an institutional shareholding score of 5.00, ranking 133rd out of 388 in the Biotechnology & Medical Research industry. Despite a quarter-over-quarter decrease of 8.92% in institutional shareholding proportion, the largest institutional share", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eldn/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T05:39:50", "published_display": "17 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQRTcxc0cxMHpWSXNOUG5PbXV1V1JjQkRVdmNzZGVSLXBteVdsaHJWdk5TZ0tZZ2w4cE1tUTlMQjlDX1JPcXdoMVdlNkowM2lrNGF0V0loQXZmQV9OZGowNDFOQzFRZnl0THBKa0R2czNPOEZIUXloMU5TX3h1RURLRzRVWGJVZXE0VU5ZbnNuZjFyT1RwalIzOGludDdfcVhZb2dTZ2VSaUlpRGMzR0l3U1NR?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ELDN Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides a financial overview of Eledon Pharmaceuticals Inc (ELDN), detailing its revenue breakdown, profitability margins, and a comparison with competitors SLGL and NVCT. Financial metrics such as gross margin, operating margin, net margin, and Return on Equity (RO", "url": "https://intellectia.ai/en/stock/ELDN/financials", "source_name": "Intellectia AI", "published_at": "2026-06-14T00:09:26", "published_display": "14 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals (ELDN) Announces Updated Results From Investigator-Initiated Trial Evaluating tegoprubart", "summary": "Eledon Pharmaceuticals (ELDN) announced updated positive results from an investigator-initiated trial of tegoprubart for type 1 diabetes patients undergoing islet cell transplantation. All 12 study participants achieved insulin independence and improved glycemic control without e", "url": "https://www.insidermonkey.com/blog/eledon-pharmaceuticals-eldn-announces-updated-results-from-investigator-initiated-trial-evaluating-tegoprubart-1779046/", "source_name": "Insider Monkey", "published_at": "2026-06-11T15:40:23", "published_display": "11 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eledon-announces-updated-data-investigator-110000620.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T11:00:00+00:00", "published_display": "08 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals stock surges on diabetes trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQnZPRjR4bjM0LVlJSVY4SmE1QXgtdzR3cjR5Z0JySmI3dUJjWmZfZzJnaTN5S21XWWlLRElkZmpHLWt3MXNqZzhRNTBEN3hSLUotU1dTQ0FjV3MxRUMzM08ySmpsb25XdGgyM3VPd3NYZDdUaFprMGV2WUplUXZMM21mZ05OLWN2YkF0N09mQTZON0ZUal82U1IzckJxMGZGam00c2ZBb1V5SmRITXlDamtEOXFXQnZQSHlTUldORFM?oc=5", "source_name": "Investing.com", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tego", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOdDlkYUlMM2ZFTkE2bkZEOURaRzI5eGtXTkdWSzkwbHF5S3dsNTVidDZJenlTYUlRR05FZ2hSc19DUmJzREgtcUFfM1FDX08tcm1FWkQ2Mk1GNGtrbFBKclo2U3VzZHZENy1DUjZBdEV5bVduSE9BUEJqdEdfOWZaT010aDAtZW5LV3hXRFo1N1A0ZkJkNUxQTE9vRFV2LXRvbGdQNDBzaGlDTTFxT25FUjlnSThDeWItcVdMazZNMnpSTEJzUnNNMHVvQVl1TnRMUjl2dkRQdEU5d2Q1X0V1Y1JOa2o?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eledon-announces-presentation-updated-data-203100060.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T20:31:00+00:00", "published_display": "04 Jun 2026 20:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-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?oc=5", "source_name": "The Manila Times", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BlackRock (NYSE) reports 4.38M-share stake in Eledon (ELDN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOWUs0ME9uZW5HT0t4ZlV1ZllFdXBrRXcwSnkzN05vcjZMc21VSGc4NE9XNlZzNTBJN3hRajdHOGFobk9vM3Yzb3JtN2UxUGhfNERMdGtGQThrQnY5S1RTWGR5bS1ORC1Vb2N5VFZ5S2lZT3pHNU13VVc5YUhQU0QzRkRlVXFjRDZUY2p0bmNJOGE3SUxicEZXNjRwblpSaVhYRFhEZnRuZ0RPbG4wSGFvOUtKQlJYZ3FNM1NnZU5PTlk4bDdTMEx2RnFaWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOa1E1MkU3c1ZrQ0lFR1ZaNUY3RlVxWUxzRmpubGk2cDdTUDhUd3R3U0M1eVNzRVJJN0daa2kyUFhIX1VUSktRXzgyLXB4RDd2NXdiUjB4c2w5aTVTekJFQ3h1YllsVHNHX0hHOG9UNzBSVmRBSm5fRjg4a2ZuYjlnZ1JhbWhYVUhacm1DM3R2NnE2VF9EeW5QZ2xVUGNSTmE4Wm1fYmJRak8xY1hH?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ELEDON PHARMACEUTICALS ($ELDN) Releases Q4 2025 Earnings, Stock Rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQbU9DTFc5RjlIckZtbjdOMm5UMXV5a3RLNWN4QXJvVjgxblpjMkJPY0lyWGRRZXZkTlZNdEVDN1hSU1d4cmh0RXJLZEpFWlF6TlVRUHN5OXcwNUFEVm1tX0x0Y3I2cHVLTTdpYkVyOGY2UVVOclE5SkRHejJnWnByU21OUlVDQWlxcHlhUEFMQlVjT1lwUjJTMklVMFplajE0bTg2M3huUk1hQ3JCRzRj?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOeXF6RVJpQ3pOcmRadmtUWE1BU2ZwZWRTb3FBVDBITl9HU01PMjVNSHdCc2tfM1hHUG11d3ZmaHNNR0lsUzUwd1JTX0NoRk5Pa0cyQjctMGl5NkpnX1hIenZkOU02eHNNU0NHVFF2dFQzLUlZclg0YWQ4SmZjZlhOZFZ6d2xWU29lbFhvUC1fOUlCa25l?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQMFZmS2dOWjBUak0xWkppb3dYclJNd0RpeVp5SUFwSzZDRE5uUXpGSHVYX1pubG9nVkQ2Rm5WZmdZeDhuQjMyblEtN2tnQUhJUHVPUjgtbUlSY2tLUU9GM3ZRdl9oNXIzX3QxbU9FajZWQkVxT1RvaTRjTTBEOXhTZXFGcWhjRWloUW9kR1ZNRUFEeEU?oc=5", "source_name": "Market source", "published_at": "2025-11-12T08:00:00+00:00", "published_display": "12 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaluating Eledon Pharmaceuticals (ELDN) Valuation Following Phase 2 BESTOW Results and Pipeline Progress", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-10T08:00:00+00:00", "published_display": "10 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals Faces Market Volatility Amid Strategic Shifts", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQM19ZZEdSTVpCeG5oWDV5LW9HeWtYRFZjUU9CZnlPZ2RNUHhfOXZiamZOclh6ZTZwcHNDZ0gyWkVybnhZVkdtSHRtWmJ6ZEtFTTE3N0xUNmRFd28wX2dOS29LREZNc0UwNWVaejQxR0ZtR0NYYUNIM0Y2X1Zvb1ZNZ2ZnTUJ3Snc?oc=5", "source_name": "timothysykes.com", "published_at": "2025-11-09T08:00:00+00:00", "published_display": "09 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Eledon Pharmaceuticals (ELDN) Valuation After Phase 2 Kidney Transplant Trial Results and Phase 3 Prospects", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQMDZhY1A0dkFUV3BZVjlzNlVjTUNjYWEzVXZOUHd1Z3hDVkJfQ3B4MEJKekVsVDV5NjRPb3RYWGhjT091X0J0a1B5RHp1ZGNPQnB0NTc5MF9KVGNDUlNVVy1NQjQtemYtMUtSQXI2T0kzVXNCVGNPNUJlUXhleDlCczhEWTYzWjhBU3FYcXR4RmpyNFlRU3NqVg?oc=5", "source_name": "Market source", "published_at": "2025-11-09T08:00:00+00:00", "published_display": "09 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Eledon Pharmaceuticals\u2019 (ELDN) Mixed Kidney Trial Results Reshape Its Competitive Edge in Transplant Care?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-08T08:00:00+00:00", "published_display": "08 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals: Stock Surge Mystery", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPWTJDaEhJTURQRXI0NW1UOXpzVVpZZVhfU2N0eG1MUU1wcjVvZGdXUWpHRXJkY2JfM0tQNXU5MEY4c2VTSnlWdUt5ZGg0R0hzVzItYWR4aks1eXdBU1ZsVEsxOWZxWFd3REIzTnVXYXZ3SW93ODRZRXVEcGFNczVMN1FSRzZPUQ?oc=5", "source_name": "StocksToTrade", "published_at": "2025-11-07T08:00:00+00:00", "published_display": "07 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With 51% ownership in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), institutional investors have a lot riding on the business", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-18T07:00:00+00:00", "published_display": "18 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Microcap Value Benchmark Index", "summary": "Eledon Pharmaceuticals, Inc. (NasdaqCM:ELDN) has been removed from the Russell Microcap Value Benchmark Index, as well as the Russell Small Cap Comp Value Benchmark and Russell 3000 Value Benchmark Indices. This news follows several recent developments for the company, including ", "url": "https://www.marketscreener.com/news/eledon-pharmaceuticals-inc-nasdaqcm-eldn-dropped-from-russell-microcap-value-benchmark-index-ce7f5fdfd989f72d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:10:11", "published_display": "29 Jun 2026 13:10", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Small Cap Comp Value Benchmark", "summary": "Eledon Pharmaceuticals, Inc. (NasdaqCM:ELDN) has been removed from the Russell Small Cap Comp Value Benchmark. The company, a clinical-stage biopharmaceutical firm, focuses on immune-modulating therapies, with its lead product, tegoprubart, targeting CD40 Ligand. This news follow", "url": "https://www.marketscreener.com/news/eledon-pharmaceuticals-inc-nasdaqcm-eldn-dropped-from-russell-small-cap-comp-value-benchmark-ce7f5fdede8af226", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:13:31", "published_display": "29 Jun 2026 10:13", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell 2000 Value Benchmark", "summary": "Eledon Pharmaceuticals, Inc. (NasdaqCM:ELDN) has been removed from the Russell 2000 Value Benchmark Index. This news follows several other announcements detailing the company's removal from various Russell indices, including the Microcap Value, Small Cap Comp Value, 3000 Value, 3", "url": "https://www.marketscreener.com/news/eledon-pharmaceuticals-inc-nasdaqcm-eldn-dropped-from-russell-2000-value-benchmark-ce7f5fdcd889f320", "source_name": "marketscreener.com", "published_at": "2026-06-29T00:11:54", "published_display": "29 Jun 2026 00:11", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Are Bullish on Top Healthcare Picks", "summary": "Wall Street analysts are showing bullish sentiment towards two healthcare companies, Definium Therapeutics (DFTX) and Eledon Pharmaceuticals (ELDN). LifeSci Capital maintained a Buy rating on Definium Therapeutics with a $63.00 price target, while also reaffirming a Buy rating on", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3023453/wall-street-analysts-are-bullish-on-top-healthcare-picks/", "source_name": "The Globe and Mail", "published_at": "2026-06-28T14:39:26", "published_display": "28 Jun 2026 14:39", "sentiment": "positive", "sentiment_pct": 86, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Eledon Pharmaceuticals, Inc. \u2013 NASDAQ:ELDN", "summary": "This article provides financial information for Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), specifically focusing on its Price to Sales (forward) metric. It appears to be a data point from TradingView, offering a snapshot of the company's valuation from a financial perspective. ", "url": "https://www.tradingview.com/symbols/NASDAQ-ELDN/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T01:09:15", "published_display": "28 Jun 2026 01:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "LifeSci Capital Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $8", "summary": "LifeSci Capital has reiterated its Buy rating on Eledon Pharmaceuticals (ELDN.US), maintaining a target price of $8. This indicates the firm's continued confidence in the company's stock performance.", "url": "https://www.moomoo.com/news/post/72135951/lifesci-capital-maintains-eledon-pharmaceuticals-eldnus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-27T23:10:12", "published_display": "27 Jun 2026 23:10", "sentiment": "positive", "sentiment_pct": 77, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Eledon Pharmaceuticals, Inc. \u2013 NASDAQ:ELDN", "summary": "The article discusses the enterprise value to EBITDA forward for Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN). It appears to be a truncated financial data page from TradingView, providing an overview of the company's financial metric without detailed analysis or figures. The conte", "url": "https://www.tradingview.com/symbols/NASDAQ-ELDN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T22:10:57", "published_display": "27 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Eledon Pharmaceuticals, Inc. \u2013 NASDAQ:ELDN", "summary": "This page displays financial information for Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN), specifically its Enterprise Value to EBIT forward. It indicates that the market was closed with no trades at the time of viewing. The content also features various navigation and information", "url": "https://www.tradingview.com/symbols/NASDAQ-ELDN/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T12:40:22", "published_display": "27 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Eledon Pharmaceuticals, Inc. \u2013 SWB:2TK", "summary": "This article provides an analysis of the Enterprise Value to Revenue (EV/R) forward for Eledon Pharmaceuticals, Inc. (SWB:2TK). It presents the current value and changes in this financial metric for the company, indicating insights for potential investors or analysts.", "url": "https://www.tradingview.com/symbols/SWB-2TK/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:40:31", "published_display": "27 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Natera (NTRA) Partners With Eledon To Put Prospera Into Phase 3 Kidney Trial", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-27T07:00:00+00:00", "published_display": "27 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Eledon Pharmaceuticals, Inc. \u2013 NASDAQ:ELDN", "summary": "This article displays the \"Price to earnings forward\" value for Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) on TradingView. It provides a quick overview of this financial metric for the company. The page appears to be a financial data snippet from a larger platform rather than a ", "url": "https://www.tradingview.com/symbols/NASDAQ-ELDN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T02:39:26", "published_display": "27 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Eledon Pharmaceuticals, Inc. \u2013 SWB:2TK", "summary": "This article focuses on the enterprise value to EBIT forward for Eledon Pharmaceuticals, Inc. (SWB:2TK) on the Stuttgart Stock Exchange. It provides a financial overview and market data, indicating that the market is currently closed with no trades. The content highlights the sto", "url": "https://www.tradingview.com/symbols/SWB-2TK/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T14:10:06", "published_display": "26 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Natera\u2019s Prospera test selected for Eledon kidney transplant trial", "summary": "Natera's Prospera kidney transplant assessment test has been chosen for Eledon Pharmaceuticals' upcoming Phase 3 clinical trial of tegoprubart. This trial, set to begin in late 2026 and enrolling 600 kidney transplant recipients globally, will use Prospera as the sole donor-deriv", "url": "https://www.investing.com/news/company-news/nateras-prospera-test-selected-for-eledon-kidney-transplant-trial-93CH-4760264", "source_name": "Investing.com", "published_at": "2026-06-25T14:41:56", "published_display": "25 Jun 2026 14:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ELDN Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Eledon Pharmaceuticals, Inc. (ELDN) stock, including analyst price targets, historical performance, and financial data. It highlights the current stock price, recent changes, market capitalization, and upcoming earnings report. The analysis al", "url": "https://www.tradingview.com/symbols/NASDAQ-ELDN/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T13:41:56", "published_display": "25 Jun 2026 13:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Natera, Eledon Partner to Use Prospera in Phase 3 Kidney Transplant Trial", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/natera-eledon-partner-prospera-phase-120547526.html", "source_name": "MT Newswires", "published_at": "2026-06-25T12:05:47+00:00", "published_display": "25 Jun 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Natera and Eledon Announce Strategic Partnership for Prospera\u2122 Monitoring in Planned Phase 3 Kidney Transplant Trial", "summary": "Natera and Eledon Pharmaceuticals have announced a strategic partnership to integrate Natera's Prospera kidney transplant assessment test into Eledon's upcoming Phase 3 clinical trial for tegoprubart, an investigational therapy aimed at preventing organ rejection. Prospera will s", "url": "https://www.businesswire.com/news/home/20260625033359/en/Natera-and-Eledon-Announce-Strategic-Partnership-for-Prospera-Monitoring-in-Planned-Phase-3-Kidney-Transplant-Trial", "source_name": "Business Wire", "published_at": "2026-06-25T10:41:56", "published_display": "25 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon trial will use Natera\u2019s Prospera test to track kidney rejection", "summary": "Natera and Eledon Pharmaceuticals have announced a strategic partnership for Eledon's planned Phase 3 kidney transplant trial. Natera's Prospera test, which detects early signs of rejection and allograft injury, will be the exclusive donor-derived cell-free DNA (dd-cfDNA) monitor", "url": "https://www.stocktitan.net/news/ELDN/natera-and-eledon-announce-strategic-partnership-for-prospera-tm-eczhnhkzl2ds.html", "source_name": "Stock Titan", "published_at": "2026-06-25T10:41:56", "published_display": "25 Jun 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10", "summary": "Noble Financial has reiterated its Buy rating for Eledon Pharmaceuticals (ELDN.US) and maintained its price target at $10. This indicates a continued positive outlook from the firm regarding the company's stock performance.", "url": "https://www.moomoo.com/news/post/71902043/noble-financial-maintains-eledon-pharmaceuticals-eldnus-with-buy-rating-maintains", "source_name": "Moomoo", "published_at": "2026-06-24T08:41:19", "published_display": "24 Jun 2026 08:41", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals, Inc. (ELDN) Discusses Updated Long-term Data From Phase 2 BESTOW Clinical Trial in Kidney Transplantation - Slideshow (NASDAQ:ELDN) 2026-06-22", "summary": "Eledon Pharmaceuticals, Inc. (ELDN) has released updated long-term data from its Phase 2 BESTOW clinical trial in kidney transplantation, which was presented in a slideshow. The trial's findings are significant for the company and its investors, highlighting ongoing developments ", "url": "https://seekingalpha.com/article/4916843-eledon-pharmaceuticals-inc-eldn-discusses-updated-long-term-data-from-phase-2-bestow-clinical", "source_name": "Seeking Alpha", "published_at": "2026-06-23T02:41:19", "published_display": "23 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon (NASDAQ: ELDN) holders approve share increase and board slate", "summary": "Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN) stockholders approved increasing authorized common stock from 300 million to 450 million shares and re-elected three Class III directors (David-Alexandre C. Gros, M.D., Jan Hillson, M.D., and James Robinson) at their annual meeting on J", "url": "https://www.stocktitan.net/sec-filings/ELDN/8-k-eledon-pharmaceuticals-inc-reports-material-event-861091862cb6.html", "source_name": "Stock Titan", "published_at": "2026-06-22T20:41:19", "published_display": "22 Jun 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon reports Phase 2 BESTOW kidney transplant data", "summary": "Eledon Pharmaceuticals announced positive long-term Phase 2 extension data for tegoprubart in kidney transplant patients, showing higher kidney function compared to traditional tacrolimus regimens. The company's shares rose following the announcement, and they plan to use these r", "url": "https://grafa.com/en/news/united-states/eledon-pharmaceuticals-phase-2-bestow-kidney-transplant", "source_name": "grafa.com", "published_at": "2026-06-22T16:40:11", "published_display": "22 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals Announces Long-Term Extension Phase 2 BESTOW Results for Tegoprubart in Kidney Transplantation", "summary": "Eledon Pharmaceuticals announced positive long-term data from its Phase 2 BESTOW clinical program for tegoprubart in kidney transplant patients. Results showed tegoprubart-treated patients maintained significantly higher mean eGFR and had fewer adverse events and no biopsy-proven", "url": "https://www.marketscreener.com/news/eledon-pharmaceuticals-announces-long-term-extension-phase-2-bestow-results-for-tegoprubart-in-kidne-ce7f5cd3df8cf62d", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T13:40:11", "published_display": "22 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cantor Fitzgerald reiterates Eledon Pharmaceuticals stock rating on kidney transplant data", "summary": "Cantor Fitzgerald has reiterated an Overweight rating on Eledon Pharmaceuticals (NASDAQ:ELDN) following positive Phase 2 study data for its kidney transplant drug candidate, tegoprubart. The drug showed stable to improved kidney function compared to standard-of-care tacrolimus. E", "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-reiterates-eledon-pharmaceuticals-stock-rating-on-kidney-transplant-data-93CH-4752620", "source_name": "Investing.com", "published_at": "2026-06-22T12:40:11", "published_display": "22 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Says Mid-Stage Data Shows Tegoprubart Offers Higher Kidney Function, Improved Outcomes Compared with Tacrolimus", "summary": "Eledon Pharmaceuticals announced that mid-stage data for its drug tegoprubart in kidney transplantation showed higher kidney function and improved outcomes compared to tacrolimus. The company's lead investigational product, tegoprubart, is an IgG1, anti-CD40L antibody aimed at im", "url": "https://www.marketscreener.com/news/eledon-says-mid-stage-data-shows-tegoprubart-offers-higher-kidney-function-improved-outcomes-compar-ce7f5cd3dc8ffe2d", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T12:40:11", "published_display": "22 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/eledon-presents-long-term-extension-110000322.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T11:00:00+00:00", "published_display": "22 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon reports kidney function benefit for tegoprubart at 18 months", "summary": "Eledon Pharmaceuticals Inc. presented positive long-term data from its Phase 2 BESTOW clinical trial, showing that tegoprubart-treated kidney transplant patients had significantly better kidney function at 18 months compared to those treated with tacrolimus. The company's shares ", "url": "https://www.investing.com/news/company-news/eledon-reports-kidney-function-benefit-for-tegoprubart-at-18-months-93CH-4752243", "source_name": "Investing.com", "published_at": "2026-06-22T11:40:11", "published_display": "22 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Presents Long-Term Extension Phase 2 BESTOW Results", "summary": "Eledon Pharmaceuticals announced new long-term data from its Phase 2 BESTOW clinical program for tegoprubart in kidney transplant patients, presented at the American Transplant Congress. The data showed sustained higher kidney function, no biopsy-proven acute rejection events aft", "url": "https://www.globenewswire.com/news-release/2026/06/22/3315172/0/en/eledon-presents-long-term-extension-phase-2-bestow-results-at-american-transplant-congress-showing-sustained-higher-kidney-function-and-improved-patient-reported-outcomes-with-tego.html", "source_name": "GlobeNewswire", "published_at": "2026-06-22T10:40:11", "published_display": "22 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink raises Eledon Pharmaceuticals price target on trial data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOSnJrUVFMTjN0ZjZnYUhPc05EZHdsa2dMdEJ6b1VlZy1TOXlESndDQjJhRDF4OGhyOHNaZ2lVMDVRWkQyLUc2OWlJVXpGVUI1OG14TzY1SDdHYzRuMERzYVBUcWhXbER6anp0WGhlZERVT0E0SjZSUGVyNnBmdXF4VlVicm9oZXBBMFRtMmU2UWxVLVR5Y3FQNWg4TEk4ZGl0REdOUE5Ub1dLZXJhZjF6LUF4ZDRQNmQtZWpZNlVVTWRrUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharma To Present At The American Transplant Congress", "summary": "Eledon Pharmaceuticals Inc. (ELDN) is scheduled to present at the American Transplant Congress (ATC) from June 20-24, 2026, in Boston. The company will host a conference call on June 22, 2026, to discuss updated data from the Phase 2 BESTOW clinical trial and new long-term data f", "url": "https://www.rttnews.com/3661226/eledon-pharma-to-present-at-the-american-transplant-congress.aspx", "source_name": "RTTNews", "published_at": "2026-06-18T12:09:01", "published_display": "18 Jun 2026 12:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals Inc (ELDN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Eledon Pharmaceuticals Inc (ELDN)'s dividend and stock split history. It states that no dividends have been distributed in the past five years and details several \"Merger 18\u21921\" stock splits that occurred on October 2, 2020. The company's curre", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eldn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:09:02", "published_display": "17 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals Inc (ELDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses Eledon Pharmaceuticals Inc (ELDN)'s revenue breakdown, noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It provides current stock performance figures for ELDN, includ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eldn/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T17:40:55", "published_display": "17 Jun 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals Inc (ELDN) Institutional Confidence", "summary": "Eledon Pharmaceuticals Inc (ELDN) has an institutional shareholding score of 5.00, ranking 133rd out of 388 in the Biotechnology & Medical Research industry. Despite a quarter-over-quarter decrease of 8.92% in institutional shareholding proportion, the largest institutional share", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eldn/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T05:39:50", "published_display": "17 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQRTcxc0cxMHpWSXNOUG5PbXV1V1JjQkRVdmNzZGVSLXBteVdsaHJWdk5TZ0tZZ2w4cE1tUTlMQjlDX1JPcXdoMVdlNkowM2lrNGF0V0loQXZmQV9OZGowNDFOQzFRZnl0THBKa0R2czNPOEZIUXloMU5TX3h1RURLRzRVWGJVZXE0VU5ZbnNuZjFyT1RwalIzOGludDdfcVhZb2dTZ2VSaUlpRGMzR0l3U1NR?oc=5", "source_name": "Market source", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ELDN Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides a financial overview of Eledon Pharmaceuticals Inc (ELDN), detailing its revenue breakdown, profitability margins, and a comparison with competitors SLGL and NVCT. Financial metrics such as gross margin, operating margin, net margin, and Return on Equity (RO", "url": "https://intellectia.ai/en/stock/ELDN/financials", "source_name": "Intellectia AI", "published_at": "2026-06-14T00:09:26", "published_display": "14 Jun 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals (ELDN) Announces Updated Results From Investigator-Initiated Trial Evaluating tegoprubart", "summary": "Eledon Pharmaceuticals (ELDN) announced updated positive results from an investigator-initiated trial of tegoprubart for type 1 diabetes patients undergoing islet cell transplantation. All 12 study participants achieved insulin independence and improved glycemic control without e", "url": "https://www.insidermonkey.com/blog/eledon-pharmaceuticals-eldn-announces-updated-results-from-investigator-initiated-trial-evaluating-tegoprubart-1779046/", "source_name": "Insider Monkey", "published_at": "2026-06-11T15:40:23", "published_display": "11 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eledon-announces-updated-data-investigator-110000620.html", "source_name": "GlobeNewswire", "published_at": "2026-06-08T11:00:00+00:00", "published_display": "08 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals stock surges on diabetes trial results", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNQnZPRjR4bjM0LVlJSVY4SmE1QXgtdzR3cjR5Z0JySmI3dUJjWmZfZzJnaTN5S21XWWlLRElkZmpHLWt3MXNqZzhRNTBEN3hSLUotU1dTQ0FjV3MxRUMzM08ySmpsb25XdGgyM3VPd3NYZDdUaFprMGV2WUplUXZMM21mZ05OLWN2YkF0N09mQTZON0ZUal82U1IzckJxMGZGam00c2ZBb1V5SmRITXlDamtEOXFXQnZQSHlTUldORFM?oc=5", "source_name": "Investing.com", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tego", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxOdDlkYUlMM2ZFTkE2bkZEOURaRzI5eGtXTkdWSzkwbHF5S3dsNTVidDZJenlTYUlRR05FZ2hSc19DUmJzREgtcUFfM1FDX08tcm1FWkQ2Mk1GNGtrbFBKclo2U3VzZHZENy1DUjZBdEV5bVduSE9BUEJqdEdfOWZaT010aDAtZW5LV3hXRFo1N1A0ZkJkNUxQTE9vRFV2LXRvbGdQNDBzaGlDTTFxT25FUjlnSThDeWItcVdMazZNMnpSTEJzUnNNMHVvQVl1TnRMUjl2dkRQdEU5d2Q1X0V1Y1JOa2o?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eledon-announces-presentation-updated-data-203100060.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T20:31:00+00:00", "published_display": "04 Jun 2026 20:31", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-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?oc=5", "source_name": "The Manila Times", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BlackRock (NYSE) reports 4.38M-share stake in Eledon (ELDN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxOWUs0ME9uZW5HT0t4ZlV1ZllFdXBrRXcwSnkzN05vcjZMc21VSGc4NE9XNlZzNTBJN3hRajdHOGFobk9vM3Yzb3JtN2UxUGhfNERMdGtGQThrQnY5S1RTWGR5bS1ORC1Vb2N5VFZ5S2lZT3pHNU13VVc5YUhQU0QzRkRlVXFjRDZUY2p0bmNJOGE3SUxicEZXNjRwblpSaVhYRFhEZnRuZ0RPbG4wSGFvOUtKQlJYZ3FNM1NnZU5PTlk4bDdTMEx2RnFaWQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Eledon Pharmaceuticals (ELDN) is an Unstoppable Stock That Could Double Your Money", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOa1E1MkU3c1ZrQ0lFR1ZaNUY3RlVxWUxzRmpubGk2cDdTUDhUd3R3U0M1eVNzRVJJN0daa2kyUFhIX1VUSktRXzgyLXB4RDd2NXdiUjB4c2w5aTVTekJFQ3h1YllsVHNHX0hHOG9UNzBSVmRBSm5fRjg4a2ZuYjlnZ1JhbWhYVUhacm1DM3R2NnE2VF9EeW5QZ2xVUGNSTmE4Wm1fYmJRak8xY1hH?oc=5", "source_name": "Market source", "published_at": "2026-04-20T07:00:00+00:00", "published_display": "20 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7wFBVV95cUxPM29WbEI2RHFfYUROWDVTS0VMSlpCWUdlTFp6NHFaQUxtV0FRaXJnRVRxUFpjeVBpdFNEdE02Z2lmclFOVEJsUmxUemxPbGNvWFNKTEJOZDhXZ2FEU21naTk5MVkzYlNkUTNOVmVqMndQNGhnQUlMSGcwWUNycGltZGpWX1lzOEdNUzJvY3l6dTFOMG9xbm9pTndIM21tUGlBU2ZMMms2S1F4UlRSWlRaZUw0VVp4RHQ4NUw1U19jV1dKcUQtdHdIOTI5UDEyNnVLZmJ1U0Y2YUlreUY0dWdmODNkMy03S3MyYWdDQ1Naa9IB9AFBVV95cUxQa0pRa0R4YWZBNXJ0VUdXMS1NdjZBRDhLdHNPb1h5bzNNTEUzQURMU0M5NWhEdmd1dmctQWtNMDNuZXpkQklLS3BfNkcteWtWa2M0QU1rZ19keG0xNVYzYzBuNW11Y1FfYzZCWUlIOXJQVl94Q2p2QXlxUGEzejVEWVgwX0pKbkdNdW12S1lieE5OeURqejNCeXhENFZaWURiRnhGeTV4dHJqWVI2QWxXeU82RmdHaVBNRldLTjBkLTJOd2lnVlFCQnFEaERlXzNsenk4LXVRei1obXFwWURtT3FJUmRkZ1dMb2x5aDRXZGNvaHZN?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ELEDON PHARMACEUTICALS ($ELDN) Releases Q4 2025 Earnings, Stock Rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQbU9DTFc5RjlIckZtbjdOMm5UMXV5a3RLNWN4QXJvVjgxblpjMkJPY0lyWGRRZXZkTlZNdEVDN1hSU1d4cmh0RXJLZEpFWlF6TlVRUHN5OXcwNUFEVm1tX0x0Y3I2cHVLTTdpYkVyOGY2UVVOclE5SkRHejJnWnByU21OUlVDQWlxcHlhUEFMQlVjT1lwUjJTMklVMFplajE0bTg2M3huUk1hQ3JCRzRj?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOeXF6RVJpQ3pOcmRadmtUWE1BU2ZwZWRTb3FBVDBITl9HU01PMjVNSHdCc2tfM1hHUG11d3ZmaHNNR0lsUzUwd1JTX0NoRk5Pa0cyQjctMGl5NkpnX1hIenZkOU02eHNNU0NHVFF2dFQzLUlZclg0YWQ4SmZjZlhOZFZ6d2xWU29lbFhvUC1fOUlCa25l?oc=5", "source_name": "Market source", "published_at": "2026-03-10T07:00:00+00:00", "published_display": "10 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQMFZmS2dOWjBUak0xWkppb3dYclJNd0RpeVp5SUFwSzZDRE5uUXpGSHVYX1pubG9nVkQ2Rm5WZmdZeDhuQjMyblEtN2tnQUhJUHVPUjgtbUlSY2tLUU9GM3ZRdl9oNXIzX3QxbU9FajZWQkVxT1RvaTRjTTBEOXhTZXFGcWhjRWloUW9kR1ZNRUFEeEU?oc=5", "source_name": "Market source", "published_at": "2025-11-12T08:00:00+00:00", "published_display": "12 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Evaluating Eledon Pharmaceuticals (ELDN) Valuation Following Phase 2 BESTOW Results and Pipeline Progress", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-10T08:00:00+00:00", "published_display": "10 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals Faces Market Volatility Amid Strategic Shifts", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxQM19ZZEdSTVpCeG5oWDV5LW9HeWtYRFZjUU9CZnlPZ2RNUHhfOXZiamZOclh6ZTZwcHNDZ0gyWkVybnhZVkdtSHRtWmJ6ZEtFTTE3N0xUNmRFd28wX2dOS29LREZNc0UwNWVaejQxR0ZtR0NYYUNIM0Y2X1Zvb1ZNZ2ZnTUJ3Snc?oc=5", "source_name": "timothysykes.com", "published_at": "2025-11-09T08:00:00+00:00", "published_display": "09 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Eledon Pharmaceuticals (ELDN) Valuation After Phase 2 Kidney Transplant Trial Results and Phase 3 Prospects", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQMDZhY1A0dkFUV3BZVjlzNlVjTUNjYWEzVXZOUHd1Z3hDVkJfQ3B4MEJKekVsVDV5NjRPb3RYWGhjT091X0J0a1B5RHp1ZGNPQnB0NTc5MF9KVGNDUlNVVy1NQjQtemYtMUtSQXI2T0kzVXNCVGNPNUJlUXhleDlCczhEWTYzWjhBU3FYcXR4RmpyNFlRU3NqVg?oc=5", "source_name": "Market source", "published_at": "2025-11-09T08:00:00+00:00", "published_display": "09 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Eledon Pharmaceuticals\u2019 (ELDN) Mixed Kidney Trial Results Reshape Its Competitive Edge in Transplant Care?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-08T08:00:00+00:00", "published_display": "08 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eledon Pharmaceuticals: Stock Surge Mystery", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxPWTJDaEhJTURQRXI0NW1UOXpzVVpZZVhfU2N0eG1MUU1wcjVvZGdXUWpHRXJkY2JfM0tQNXU5MEY4c2VTSnlWdUt5ZGg0R0hzVzItYWR4aks1eXdBU1ZsVEsxOWZxWFd3REIzTnVXYXZ3SW93ODRZRXVEcGFNczVMN1FSRzZPUQ?oc=5", "source_name": "StocksToTrade", "published_at": "2025-11-07T08:00:00+00:00", "published_display": "07 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With 51% ownership in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), institutional investors have a lot riding on the business", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-10-18T07:00:00+00:00", "published_display": "18 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 101, "total_relevant": 62, "sentiment_summary": {"positive": 20, "negative": 4, "neutral": 38, "score": 57, "total": 62, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 77, "events": [{"event": "general", "label": "Market update", "weight": 15.75, "count": 28}, {"event": "earnings", "label": "Earnings", "weight": 11.55, "count": 23}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "deals", "label": "Deals and strategy", "weight": 1.65, "count": 3}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}], "positive_events": 20, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 3.85, "latest_week": "2026-07-10", "one_week_move": -2.5, "four_week_move": 7.8, "twelve_week_move": -3.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.279492, "market_dynamics_buy_signal": false, "relative_strength": 17.714952, "fair_value_gap": 42.8, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 47.2475, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.5% over one week, +7.8% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 10}, {"label": "TradingView", "count": 8}, {"label": "simplywall.st", "count": 7}, {"label": "Investing.com", "count": 5}, {"label": "www.marketscreener.com", "count": 4}, {"label": "GlobeNewswire", "count": 4}, {"label": "Stock Titan", "count": 3}, {"label": "TradingKey", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 54}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 28}, {"label": "Earnings", "count": 23}, {"label": "Analyst action", "count": 6}, {"label": "Deals and strategy", "count": 3}, {"label": "Regulatory and legal", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "77/100 classification confidence."}, {"label": "Company focus", "value": "54", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-2.5% over one week, +7.8% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from Russell Microcap Value Benchmark Index"}], "updated_at": "2026-07-16T07:05:07.634519+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}